VERAXA Biotech (NASDAQ: VRXA) has released new in vitro proof-of-concept data supporting its BiTAC-ADC platform, a technology designed to improve the selectivity of antibody-drug conjugates (ADCs) in cancer treatment. The company presented the findings as it prepares to engage with potential partners at the BIO International Convention 2026 in San Diego.
The data demonstrated that VERAXA's BiTAC-ADC technology could distinguish between breast cancer cells and healthy cells in laboratory studies, showing selective activity against cancer cells while sparing normal cells. Additionally, the platform achieved dose-dependent destruction of three-dimensional tumor cell spheroids, which more closely mimic solid tumor architecture than traditional two-dimensional cultures. These results suggest that the BiTAC approach may reduce off-target toxicity, a common limitation of conventional ADCs.
VERAXA's proprietary BiTAC (Bispecific T-cell Activated Conjugate) platform is designed to activate therapeutic effects only within targeted tumor cells, thereby improving precision. The company maintains a diversified oncology pipeline of antibody-based formats, including ADCs, T-cell engagers (TCEs), and other antibody-based therapeutics. At the convention, VERAXA will present both its BiTAC-ADC and BiTAC-TCE platforms for potential strategic collaborations.
The announcement follows VERAXA's recent listing on the NASDAQ Capital Market under the ticker VRXA, after completing a business combination with Voyager Acquisition Corp. The company is now positioned to advance its pipeline and seek partnerships to accelerate development.
While the BiTAC-ADC platform remains in early development, the new data provides a critical validation of its mechanism. If successfully translated to clinical settings, the technology could address significant unmet needs in oncology by enabling more precise delivery of potent chemotherapeutic agents to tumors, potentially improving efficacy and reducing side effects for patients.
VERAXA's focus on next-generation cancer therapies aligns with industry trends toward precision medicine. The ability to selectively target cancer cells while preserving healthy tissue is a key goal for many developers, and the BiTAC platform offers a novel approach to achieving this. The company's engagement with potential partners at BIO 2026 could lead to collaborations that provide resources and expertise to move the platform into clinical trials.
For more information on VERAXA Biotech and its pipeline, including forward-looking statements and risk factors, refer to the company's filings with the SEC. The latest news and updates are available in the company's newsroom at https://ibn.fm/VRXA.
